Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Ibara will drive AI-powered clinical research innovation
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Subscribe To Our Newsletter & Stay Updated
